Skip to main content

Health condition

Adrenoleukodystrophy, an ABCD1 defect, four phenotypes and a real curative window.

A rare X-linked condition where identifying disease early - by cascade testing, VLCFA and MRI - opens the door to allogeneic transplant or gene therapy while it still helps.

A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE, NHS England highly specialised services, EMA and peer-reviewed neurogenetics sources.

  • 03

    Current for 2026

    Reflects modern practice including allogeneic HSCT and elivaldogene autotemcel (Skysona) gene therapy for early cerebral ALD.

Key facts

X-ALD at a glance.

The essentials, in plain English - what it is, who it affects, how it is diagnosed and where curative therapy fits.

  • What it is

    X-linked adrenoleukodystrophy (X-ALD) - an ABCD1 gene defect that impairs peroxisomal beta-oxidation of very long chain fatty acids (VLCFA).

  • Who it affects

    Predominantly boys and men (X-linked), but heterozygous women commonly develop adrenomyeloneuropathy in adulthood.

  • Main phenotypes

    Childhood cerebral ALD, adult adrenomyeloneuropathy (AMN), Addison-only phenotype and presymptomatic disease.

  • Key test

    Plasma VLCFA is the screening biochemical marker - ABCD1 sequencing confirms the diagnosis.

  • Curative window

    Allogeneic HSCT or elivaldogene autotemcel gene therapy can halt early cerebral ALD if the Loes MRI score is 0 to 9.

  • Adrenal replacement

    Around 80 per cent of affected boys and men develop primary adrenal insufficiency needing glucocorticoid and mineralocorticoid replacement.

Why this guide matters

A rare disease where timing is everything.

The three points below shape everything else on this page - and explain why cascade testing and MRI surveillance are worth the effort.

  • One gene, several diseases

    A single ABCD1 defect can produce cerebral ALD in a boy, AMN in his uncle and Addison-only disease in a cousin - the same variant, very different journeys.

  • The MRI is the clock

    For cerebral ALD, curative therapy works while the Loes score is low and neurology is preserved - surveillance MRI in at-risk boys is the whole point.

  • Adrenals never wait

    Around 80 per cent of affected boys and men will develop adrenal insufficiency at some stage - a Synacthen test and steroid plan are non-negotiable.

How the diagnosis is made

From suspicion to a family-wide plan.

The steps a UK neurometabolic MDT will normally follow, in order - so you know what to expect and why each one matters.

  1. 01

    Assessing

    Clinical suspicion

    Boys with new behavioural or cognitive change, unexplained adrenal insufficiency, or adult men with progressive spastic paraparesis warrant VLCFA testing.

  2. 02

    Assessing

    Plasma VLCFA panel

    A raised C26:0 and elevated C26:0/C22:0 and C24:0/C22:0 ratios are the biochemical fingerprint of X-ALD.

  3. 03

    Assessing

    ABCD1 genetic confirmation

    Sanger or next-generation sequencing of the ABCD1 gene confirms the pathogenic variant and enables family cascade testing.

  4. 04

    Confirming

    Brain MRI with Loes scoring

    MRI detects the demyelinating lesions of cerebral ALD - the Loes score (0 to 34) grades severity and guides curative eligibility.

  5. 05

    Confirming

    Adrenal function assessment

    Baseline 9am cortisol, ACTH and a short Synacthen (ACTH stimulation) test detect primary adrenal insufficiency early.

  6. 06

    Preparing

    Cascade family testing

    Genetic counselling and cascade testing of siblings, sons, daughters and maternal relatives identifies presymptomatic cases in time to act.

  7. 07

    Preparing

    Surveillance and MDT referral

    Presymptomatic boys enter an MRI surveillance programme - typically 6-monthly between ages 3 and 12 - within a specialist neurometabolic MDT.

Typical timeline: a symptomatic presentation to a full family plan within weeks in a specialist centre.

Symptoms

What X-ALD actually looks like.

The pattern depends on the phenotype - cerebral ALD in boys, adrenomyeloneuropathy in adults, Addison-only in some, and nothing at all in others.

  • Behavioural or cognitive change (boys)

    New inattention, school decline, personality change or auditory processing problems in a boy aged 3 to 10 - a red flag for cerebral ALD.

  • Progressive spastic paraparesis

    Slowly worsening stiffness and weakness in the legs in adult men or heterozygous women - the hallmark of adrenomyeloneuropathy.

  • Peripheral neuropathy

    Numbness, tingling or loss of vibration and joint position sense - common in AMN and often subtle at first.

  • Bladder and bowel dysfunction

    Urinary urgency, frequency, hesitancy or incontinence and bowel changes reflect spinal cord involvement in AMN.

  • Adrenal insufficiency (Addisonian)

    Fatigue, weight loss, salt craving, hyperpigmentation and low blood pressure - often the earliest manifestation, sometimes in childhood.

  • Sexual dysfunction

    Erectile dysfunction and reduced libido are common in men with AMN, partly neurological and partly endocrine.

  • Adult heterozygous women

    Around 80 per cent develop AMN-like features by age 60 - typically milder and later than in affected men, but real and often missed.

  • Red flag - Addisonian crisis

    Vomiting, dehydration, low sodium and shock in a known or suspected case is an emergency - needs immediate IV hydrocortisone.

Treatment

How X-ALD is treated in the UK.

Curative cellular therapy in a narrow window for cerebral ALD, adrenal replacement for the endocrine side, and long-term rehabilitation for AMN.

  • Allogeneic HSCT

    Matched-donor haematopoietic stem cell transplant halts early cerebral ALD when Loes score is 0 to 9 and neurological function is preserved.

  • Elivaldogene autotemcel (Skysona)

    Autologous gene therapy adding a functional ABCD1 gene to the patient s own stem cells - EMA and FDA approved (2021 to 2022) for early cerebral ALD.

  • Glucocorticoid replacement

    Hydrocortisone (or prednisolone) mimics cortisol - dose split across the day and doubled during illness, with an emergency injection kit.

  • Mineralocorticoid replacement

    Fludrocortisone replaces aldosterone - guided by blood pressure, sodium, potassium and plasma renin.

  • Physiotherapy and rehabilitation

    Structured neurophysiotherapy maintains gait, balance and function in AMN - a core part of long-term care.

  • Spasticity and bladder management

    Baclofen, tizanidine, gabapentin and bladder-directed drugs or intermittent self-catheterisation ease day-to-day symptoms.

  • Genetic counselling and cascade

    Family testing, reproductive options, prenatal diagnosis and preimplantation genetic testing sit at the heart of long-term care.

  • MDT and NHS specialist pathway

    Care through NHS England highly specialised metabolic services - with NICE-approved gene therapy delivered via designated centres.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, EMA product information and consensus statements from international neurometabolic groups, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your neurologist, endocrinologist or metabolic specialist knows your history and can tell you which parts apply to you.

  • NHS England. Highly specialised services - inherited metabolic disorders.

  • NICE. Elivaldogene autotemcel (Skysona) technology appraisal and pathway guidance.

  • European Medicines Agency (EMA). Skysona - summary of product characteristics.

  • Engelen M et al. X-linked adrenoleukodystrophy - clinical practice guidelines. Orphanet Journal of Rare Diseases.

  • Kemp S et al. ALD Connect and Leukodystrophy consensus statements on newborn screening and surveillance.

Red flags

When X-ALD needs urgent attention.

Most of the disease is managed in a specialist MDT - these are the situations that need same-day contact and not next appointment.

  • Addisonian crisis

    Vomiting, dehydration, low blood pressure and confusion is a medical emergency - immediate parenteral hydrocortisone and IV fluids save lives.

  • New cognitive or behavioural change

    Any new school, behaviour or learning decline in a boy with known ALD is a red flag - urgent MRI to look for cerebral disease.

  • Rapidly rising Loes score

    A jump in MRI Loes score between surveillance scans triggers urgent MDT review for HSCT or gene therapy while the window is still open.

  • Missed steroid doses

    Skipped doses, vomiting or illness without stress dosing can precipitate crisis - a written sick-day plan is essential.

  • Presymptomatic boy without surveillance

    An untested at-risk boy is the biggest missed opportunity - cascade testing and MRI programmes exist specifically to prevent this.

  • Sudden gait deterioration in AMN

    A step-change in walking, new sensory level or bladder retention warrants MRI to exclude a superimposed cause.

  • Undiagnosed adrenal insufficiency

    Fatigue, weight loss and hyperpigmentation in a boy or man with an ALD family history should trigger urgent adrenal testing.

  • Pregnancy in a carrier

    Reproductive planning matters - prenatal or preimplantation options should be discussed early, not in the third trimester.

  • Post-HSCT or gene-therapy complications

    Cytopenias, infections or new neurology after cellular therapy need same-day contact with the treating specialist centre.

Living with it

A long-term condition, with a plan that grows with you.

Four things that make the biggest difference year to year - a written steroid plan, regular surveillance, rehab that keeps pace with the disease, and cascade testing across the family.

A quiet reminder

Prepared beats perfect, every time.

A steroid kit, an alert card and a rehearsed sick-day plan protect life more than any single treatment decision.

  1. 01 Plan

    Steroid sick-day rules

    A written plan for doubling doses in illness, an emergency hydrocortisone injection kit and a medical alert card should always be to hand.

  2. 02 Monitor

    Keep surveillance appointments

    Regular MRI in at-risk boys and yearly neurology and endocrine review in adults catch problems while they are still treatable.

  3. 03 Support

    Rehab and mobility

    Physiotherapy, orthotics and, when needed, mobility aids protect independence in AMN over decades.

  4. 04 Family

    Cascade testing matters

    Testing relatives is one of the most powerful interventions in this disease - it is never too late to have the conversation.

Frequently asked

Everything we get asked about X-ALD.

Quick answers on diagnosis, cerebral ALD, AMN, HSCT, gene therapy and newborn screening.

  • What is adrenoleukodystrophy?

    X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder caused by variants in the ABCD1 gene. The resulting protein defect impairs the breakdown of very long chain fatty acids in peroxisomes, and these fatty acids accumulate in the brain, spinal cord, adrenal glands and testes. The condition has several phenotypes ranging from childhood cerebral ALD to adult adrenomyeloneuropathy and isolated adrenal insufficiency.

  • How is X-ALD diagnosed?

    The starting point is a plasma very long chain fatty acid (VLCFA) panel, which shows a raised C26:0 and elevated C26:0/C22:0 and C24:0/C22:0 ratios. Genetic testing of the ABCD1 gene confirms the diagnosis. In boys with a possible cerebral phenotype, brain MRI with Loes scoring guides treatment decisions, and a short Synacthen test assesses adrenal function.

  • Is there a cure for cerebral ALD?

    Allogeneic haematopoietic stem cell transplant (HSCT) can halt cerebral disease if performed early - typically when the Loes MRI score is 0 to 9 and neurological function is still preserved. Elivaldogene autotemcel (Skysona), an autologous gene therapy approved by the FDA and EMA in 2021 and 2022, offers an alternative for boys without a suitable donor. Neither therapy reverses established damage, which is why early surveillance is so important.

  • What is adrenomyeloneuropathy?

    AMN is the adult form of X-ALD. It typically presents in the third or fourth decade with slowly progressive spastic paraparesis (stiffness and weakness of the legs), peripheral neuropathy, bladder dysfunction and, in men, sexual dysfunction. Around 80 per cent of heterozygous women also develop AMN-like features by their 60s. HSCT and gene therapy are not established treatments for AMN, so care focuses on rehabilitation, symptom control and adrenal management.

  • Do all boys with ABCD1 variants develop cerebral disease?

    No. Only around 35 to 40 per cent of boys with an ABCD1 variant develop the cerebral phenotype in childhood, but there is no reliable way to predict who will. That is why regular MRI surveillance from around age 3 to 12 is offered - so that anyone who does develop cerebral disease can be identified while curative therapy is still an option.

  • Is there newborn screening in the UK?

    Newborn screening for X-ALD is offered in a number of US states and some European regions but is not currently part of the routine UK newborn bloodspot programme in 2026. Diagnosis in the UK usually follows a symptomatic presentation or, importantly, cascade testing after a family member is diagnosed. Genetic counselling and cascade testing of at-risk relatives is one of the most valuable actions after any new diagnosis.

Related content

Keep reading.